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PURPOSE: Brugada syndrome is an autosomal dominant arrhythmia condition caused by 
genetic mutations affecting the cardiac conduction system. It is characterized by an abnormal 
electrocardiogram pattern and a predisposition to syncope and sudden cardiac death. Penetrance 
is incomplete and expressivity varies greatly within families. This condition is endemic in 
Southeast Asia, but was described in North America and Europe in 1992. Due to its novelty and 
complexity there is a scarcity of informational resources. The first aim of this project was to gain 
insight from individuals and families with Brugada syndrome and to use this information to 
accomplish the second aim: an educational resource well-suited for families coping with Brugada 
syndrome. The public health relevance of this project reflects its application to genetic 
counseling: the development of patient educational resources involves a careful assembly of 
content and design with attention to patient needs.  
METHODS: Ten participants completed a questionnaire which addressed general understanding 
of the condition, personal experiences, terms and concepts related to Brugada syndrome, and 
individual perspectives. The responses to the questionnaire were used to help shape an 
educational resource.  
RESULTS: Analysis of the questionnaire responses revealed that some main concepts are well-
understood by this study population, while there is considerable lack of understanding of other 
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important concepts associated with Brugada syndrome. Overall participants expressed needs for 
more information and tools for coping with the condition.  
CONCLUSION: A two part educational resource was created to address these needs. A short 
introductory pamphlet was produced for use as an initial introduction to the condition and an in-
depth resource called Brugada syndrome: A Guide for Families was created. The resources 
include patient-friendly explanations of symptoms, diagnosis, treatment, children, inheritance, 
genetic testing, and support resources. 
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 PREFACE 
 
I could not have completed this project without the families who participated. They motivated 
me to start this project and I have them to thank for my continued interest in this field. Many of 
them dealt with a diagnosis of Brugada syndrome in a time when few doctors had even heard of 
it, let alone their family and friends. They are truly inspiring.  
I would like to thank my family for supporting me when I decided to change career paths. 
They mustered up enthusiasm and confidence when it could not have been easy and if they were 
skeptical it never showed. Thank you to Peter for listening to the good and the bad and for 
helping me through the last four years of school. Here’s to a lifetime of weekends. 
 I have heaps of gratitude to Dr. Barry London and Becky Gutmann for teaching me so 
much about Brugada syndrome and cardiovascular genetics, and instilling a lifelong interest. I 
had the pleasure of working with them over the last two years and I learned a great deal. I 
appreciate my thesis committee for their advice, their flexibility, and for allowing me to pursue 
this project. Thank you to Luba Djurdjinovic for mentoring me and suggesting I look into 
cardiovascular genetics “because it is the future.” She was right. Many thanks to Robin Grubs 
and Betsy Gettig for sharing their wisdom and offering terrific support while running a fantastic 
program- I have never doubted my decision to come here. Finally to my classmates, a lovely and 
welcoming bunch, thank you for an enjoyable two years and a great start to lifelong friendships. 
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1.0  INTRODUCTION 
Brugada syndrome is a life-threatening condition that can manifest in seemingly healthy 
individuals with structurally normal hearts. A diagnosis is often the result of an unexpected event 
such as fainting or sudden cardiac death. As a relatively new condition with clinical and genetic 
complexities, health care professionals and patients encounter a great deal of uncertainty 
regarding Brugada syndrome. This thesis is the summary of a project intended to develop an 
educational module tailored for individuals and families with Brugada syndrome. 
The motivation for this project arose through communication with families enrolled in a 
study at the University of Pittsburgh called Familial Studies in Cardiovascular Disease. The 
principal investigator of this study is Dr. Barry London. Through contact with these families it 
became clear that the uniqueness and novelty of Brugada syndrome makes it difficult to locate 
adequate information about the condition through traditional resources. Print materials written 
about Brugada syndrome for the general public are scarce. The internet resources on Brugada 
syndrome are limited as well. As with any condition, once a diagnosis is made there are 
questions about details, risks, and how the diagnosis will affect different aspects of life. Without 
traditional publicly accessible resources it is difficult to address these questions. The individuals 
enrolled in such research as Dr. London’s study have the benefit of access to cardiologists and 
nurses who have studied Brugada syndrome extensively and have experience with the types of 
questions and concerns that often arise. It seems that if these individuals in the study have found 
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the limitations of information access frustrating it is likely true that individuals without such 
access to a research team also struggle with the confusion and rarity of this condition.   
Brugada syndrome is complex and still has many uncertainties. It introduces the risk of 
sudden cardiac death as a real tangible entity, something that most people never have to 
encounter. The goal of this project was to enable patient empowerment through easily accessible 
information in order to address this complexity, uncertainty, and risk. An individual with the 
diagnosis will likely rely on his or her family for support, and as an autosomal dominant 
condition the implications of a diagnosis stretch beyond the individual. As Brugada syndrome 
affects the family as a whole, the needs of both the individual and the family must be considered 
so that they have the tools to cope with the condition. A key role of a genetic counselor is to 
create educational materials that can help individuals and families understand their condition and 
its implications. In order to accomplish this task, genetic counselors can elicit information from 
their patient population in order to determine the appropriate content and design that will best 
serve that population.  
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2.0  AIMS OF THE STUDY 
2.1 SPECIFIC AIM 1: ASSESSMENT OF KNOWLEDGE AND INSIGHT TO 
EVALUATE THE INFORMATIONAL AND EMOTIONAL NEEDS OF INDIVIDUALS 
AND FAMILIES WITH BRUGADA SYNDROME 
The first aim of this study was to assess the general knowledge and understanding of Brugada 
syndrome among individuals who have the condition and their families. It expected to obtain 
individual insight and advice from participants based on their personal experiences with the 
condition. Lastly, it sought to explore the psychosocial needs of these families arising from their 
experience with the condition.  
2.2 SPECIFIC AIM 2: CREATION OF AN EDUCATIONAL RESOURCE 
The second aim of this study was to combine background research on the condition and the 
information gained from the first aim in order to guide the creation of an educational resource 
that could target the informational and emotional needs of families with Brugada syndrome. 
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3.0  BACKGROUND AND SIGNIFICANCE 
3.1 EPIDEMIOLOGY 
Brugada syndrome is an autosomal dominantly inherited arrhythmia condition that confers a 
predisposition for syncope and sudden cardiac death. Brugada syndrome is characterized by an 
abnormal electrocardiogram pattern, which shows a right bundle branch block and persistent ST-
segment elevation in leads V1-V3 (Brugada et al., 1992; Antzelevitch et al., 2005). The 
condition was first described in 1992 by the brothers Pedro and Josep Brugada, for whom the 
condition is named (Brugada et al., 1992). Since 1992, many more case reports and publications 
on the condition have followed, leading to various studies and research projects as well as 
several mutation discoveries.  
Sudden cardiac death is indeed a public health concern as it accounts for an estimated 
300,000 to 400,000 annual deaths. Sudden cardiac death is unexpected in seemingly healthy and 
young individuals. Brugada syndrome is reportedly responsible for greater than 4% of all sudden 
deaths and 20% of all sudden deaths in patients with normal heart structure (Antzelevitch et al., 
2005). Sudden death has non-cardiac causes such as seizure, asthma, stroke, and pulmonary 
embolism. Syncope is the medical term for fainting or a loss of consciousness and has many 
possible causes, which can be difficult to delineate.   
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Brugada syndrome is considered a channelopathy because it is an electrical disorder 
rather than a structural disease. Channelopathies are a family of conditions in which an error 
within a cardiac channel causes an electrical malfunction that leads to the development of an 
arrhythmia. It is possible for structural heart disease and a channelopathy to co-exist due to 
multiple and separate causes. Other channelopathies have been described and are also known 
causes of sudden cardiac death. 
Brugada syndrome is endemic in Southeast Asia, where it is known locally by several 
names: Lai tai or “death during sleep” in Thailand, bangungut or “moaning and dying during 
sleep” in the Philippines, and pokkuri or “sudden unexpected death at night” in Japan 
(Nademanee et al., 1997). In Southeast Asia Brugada syndrome is known as sudden unexplained 
death syndrome (SUDS) and sudden unexplained nocturnal death syndrome (SUNDS). 
Molecular and clinical analysis of SUDS/SUNDS patients has verified that these conditions are 
Brugada syndrome (Vatta et al., 2002). The public health impact of Brugada syndrome is 
substantial in Southeast Asia. A survey of the cause of death in young Thai men found that the 
annual SUDS death rate was up to 38 per 100,000 men ages 20-49, making it the leading natural 
cause of death in young Thai men (Nademanee et al., 1997).  
The prevalence of Brugada syndrome is estimated to range between 5 and 66 per 10,000 
worldwide (Wilde et al., 2002). The prevalence is calculated to be 5 in 10,000 in Southeast Asia 
(Nademanee 1997). In Japan, a study found the prevalence of type 1 Brugada electrocardiogram 
(ECG) pattern to be 12 in 10,000 residents and the combined prevalence of type 2 and type 3 
ECG patterns to be 58 in 10,000 (Miyasaka et al., 2001). The true prevalence is not known due to 
the concealment of ECG patterns in many individuals. The prevalence of Brugada syndrome 
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among children is less than among adults, yet children are also susceptible to sudden cardiac 
death. Brugada syndrome is a known cause of sudden infant death syndrome (SIDS).  
3.2 NATURAL HISTORY 
An ion channel malfunction in the heart has the ability to cause an arrhythmia. Non-sustained 
(self-terminating) ventricular tachycardia or fibrillation can cause syncope, seizure, or sleep 
disturbance.  Sustained ventricular fibrillation leads to sudden cardiac death, which presents as 
Sudden Infant Death Syndrome (SIDS) in infants. Other arrhythmias are also seen: 
supraventricular arrhythmias occur in 20% of patients with Brugada syndrome and atrial 
fibrillation is seen in 10-20% (Morita et al., 2002). 
Penetrance is unpredictable, ranging from a normal asymptomatic lifespan to sudden 
cardiac death in the infant stage. Even within families the expressivity of the condition is highly 
variable. The average age of diagnosis, often prompted by an aborted sudden cardiac death or 
syncopal episode, is 41-42 years (Brugada et al., 2002; Priori et al., 2002; Antzelevitch et al., 
2006). The actual range of ages at presentation has varied from the neonate to 84 years 
(Antzelevitch et al., 2006). Despite the autosomal dominant nature of transmission in Brugada 
syndrome, the clinical phenotype is seen in men 8 to 10 times more than it is seen in women 
(Eckardt et al., 2007). This phenotypic disparity is most likely due to gender differences in ionic 
currents and sex hormones.  
Individuals with Brugada syndrome may present to a doctor for reasons such as dizziness, 
syncope, palpitations, or unrelated problems that prompt an electrocardiogram. Brugada 
syndrome may manifest with recurrent ventricular tachyarrhythmias, which are referred to as an 
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“electrical storm” (Anztelevitch et al., 2005). In some cases sudden cardiac death is the first 
symptom of Brugada syndrome in a seemingly unaffected individual. Unlike most other 
arrhythmia disorders, neither exercise nor excitement triggers an arrhythmia in Brugada 
syndrome. Most ventricular arrhythmias in Brugada syndrome occur at rest or while sleeping. 
Most likely this is due to factors such as sympatho-vagal balance, hormones, and metabolic 
factors that are altered during rest (Benito et al., 2008; Antzelevitch et al., 2005). Other risk 
factors include fever, medications, and certain drugs. Fever associated with illness or simple 
overheating can precipitate an event. Fever is the most frequent cause of ventricular fibrillation 
leading to syncope or sudden cardiac death in children with Brugada syndrome (Probst et al., 
2007). 
Sudden infant death syndrome (SIDS), also called crib-death or cot-death, is the sudden 
unexplained death of an infant within the first year of life. SIDS claims over 2000 infants 
annually in the United States (Heron et al., 2010). Advances in genetic testing have led to the 
utility of molecular autopsy. Post mortem molecular testing of SIDS infants found mutations in 
several of the genes known to be responsible for Brugada syndrome (Tester et al., 2009). 
3.3 DIAGNOSIS 
In 2002 and 2005, two consensus conferences were held to define the diagnostic criteria for 
Brugada syndrome. Three electrocardiogram (ECG) patterns are recognized. A type 1 ECG 
pattern is characterized by a coved ST-segment elevation greater than or equal to 2mm, followed 
by a negative T wave. A type 2 ECG pattern is characterized by an ST-segment elevation, 
followed by a positive or biphasic T wave, which results in a saddle-back configuration. A type 3 
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ECG pattern demonstrates a right precordial ST-segment elevation less than or equal to 1mm, 
followed by a saddle-back or coved-type pattern (Benito et al., 2008). ECG patterns in Brugada 
syndrome patients often fluctuate over time and can span from normal to a spontaneous type 1 
pattern in a single patient. Symptomatic patients may show a longer QRS duration or 
supraventricular arrhythmia (Benito et al., 2008). The sensitivity of ECG testing in a Brugada 
syndrome patient can be improved by placing the right precordial leads on the second or third 
intercostal spaces (Sangwatanaroj et al., 2001). 
Diagnosis is confirmed by a type 1 pattern ST-segment elevation in 2 or more right 
precordial leads (V1-V3) in the presence or absence of a sodium channel blocking agent, along 
with at least one other feature from the following list: documented ventricular fibrillation, 
polymorphic ventricular tachycardia, family history of sudden cardiac death before age 45, 
coved-type electrocardiograms in family members, history of syncope, history of nocturnal 
disturbances in breathing patterns, or inducibility of ventricular tachycardia with programmed 
electrical stimulation (Antzelevitch et al., 2005). Type 2 and type 3 patterns are not diagnostic. 
However if an individual has a type 2 or type 3 pattern that converts to type 1 after 
administration of sodium channel blockers and the clinical criteria is present, it is considered 
diagnostic (Antzelevitch et al., 2006). 
Electrocardiogram patterns can be hidden in Brugada syndrome patients and may be 
unmasked clinically by drug challenge testing as indicated above. Drug challenge testing uses 
intravenous sodium channel blockers in an attempt to unmask a Brugada ECG. The sodium 
channel blockers used include ajmaline, flecainide, procainamide, pilsicainide, disopyramide, 
and propafenone (Antzelevitch et al., 2006). During testing a patient is monitored by ECG and 
the challenge is stopped if an arrhythmia develops (Benito et al., 2008). Drug challenge testing is 
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often used in families when there is a known diagnosis, but a mutation is not known. In this type 
of situation individuals can be evaluated to help delineate their risk and determine appropriate 
management options. A Brugada syndrome ECG pattern may also be unmasked accidentally by 
fever, vagotonic agents, alpha-adrenergic agonists, beta-adrenergic blockers, cyclic 
antidepressants, hyperkalemia or hypokalemia, hypercalcemia, a combination of glucose and 
insulin, excessive consumption of alcohol, or cocaine use (Hedley et al., 2009). 
Family history is an important indicator for Brugada syndrome. Suspicious family history 
includes sudden cardiac death, unexplained sudden death before 45, death during sleep, SIDS, 
syncope, dizzy spells, seizures, palpitations, abnormal electrocardiograms, and individuals with 
pacemakers or implantable cardioverter defibrillators. Indicators of Brugada syndrome are often 
masked by female carriers and deaths at younger ages due to unrelated causes, i.e. motor vehicle 
accident. Family history is taken into consideration for risk stratification. 
3.4 MANAGEMENT 
An implantable cardioverter device (ICD) is the only effective therapy available today. Certain 
drugs have been investigated in an attempt to find a pharmacological approach to rebalancing 
cardiac currents. Quinidine and Tedisamil, both class IA antiarrhythmics may be protective 
because they block potassium channels (Antzelevitch et al., 2005). Avoidance of specific 
medications and drugs is an integral part of lowering one’s risk. The rapid treatment of fever is 
important in Brugada syndrome as fever often precipitates arrhythmogenic events. 
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3.4.1 Risk factors 
Gender related differences in Brugada syndrome that were noted anecdotally among families and 
cultures have been validated in recent clinical studies. In Thailand the fact that the primarily 
affected individuals are men has led to a superstition about evil spirits and a tradition in which a 
man dresses as a woman when he goes to sleep in order to fool evil spirits (Eckardt, 2007). 
Studies have shown that the anecdotal stories are explained by male versus female differences in 
testosterone levels and potassium currents (Shimizu et al, 2007). Other hormones such as 
estradiol and thyroid are also known to alter important ionic currents. However this study did not 
find a difference among Brugada patients and controls. Thus it appears that female hormones are 
not protective, but being male is a natural risk factor. The results from Shimizu et al also 
suggested that rapid weight loss would be expected to raise testosterone levels and possibly 
trigger a Brugada phenotype, much like a fever. Other risk factors include fever, ethnicity 
(Southeast Asian), and history of syncope or abnormal electrocardiogram. Cocaine use, alcohol 
consumption, and certain prescription medications are avoidable risk factors. 
Most often a male is the first affected family member that brings attention to the 
condition. The 8 to 1 male to female ratio has implications for research bias. Approximately 71-
77% of patients in clinical studies of Brugada syndrome have been male (Benito, 2008). Thus the 
expression of Brugada syndrome in females is not as well studied.  
3.4.2 Risk stratification 
Risk stratification during diagnosis is important for proper management. Risk stratification 
remains controversial in the electrophysiology community. Gender differences in penetrance are 
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an important factor in proper risk management. For men the presence of previous symptoms, 
including syncope and aborted sudden cardiac death, is the most useful predictor for cardiac 
events. The best predictor for cardiac events in women is a longer PR interval (Benito, 2008).  
Approximately 25% of individuals with clinical Brugada syndrome experience sudden death or 
ventricular fibrillation during their lifetime (Benito et al., 2008). Prognosis in individual Brugada 
syndrome patients is difficult to predict. Clinicians tend to rely on risk markers in an individual 
in order to determine their risk for a cardiac event. The presence of symptoms such as fainting 
before actual diagnosis, presence of a spontaneous type 1 ECG, and male gender all appear to 
increase risk. The 8 to 1 male to female ratio also has implications for risk estimation. Although 
25% is often quoted as the approximate risk, this estimate is most likely an overestimate for 
women. 
3.4.3 Therapy 
An implantable cardioverter defibrillator (ICD) is the only effective therapy for symptomatic 
Brugada syndrome patients. An ICD reverts ventricular fibrillation through electrical shock, 
which prevents sudden cardiac death. Indications for ICD implantation are divided into classes. 
Class I indicates there is clear evidence that an ICD is useful and effective, class II indicates 
there is conflicting evidence: IIa means evidence weighs in the favor of an ICD while IIb means 
that the usefulness and efficacy of an ICD is not as well established (Antzelevitch et al., 2005). 
Individuals who have experienced an aborted sudden death are considered to be at risk for 
another event and an ICD is clearly indicated. An ICD is also indicated in individuals with a 
history of syncope and a spontaneous type 1 ECG. When there is a history of syncope and a type 
1 ECG revealed by drug challenge the indication is considered class IIa and ICDs are often 
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prescribed. Similarly if a person is asymptomatic, but has a spontaneous type 1 ECG and is 
inducible for ventricular fibrillation or tachycardia the indication is also considered class IIa. In 
contrast, asymptomatic individuals who show a type 1 ECG after drug challenge testing and have 
a family history of sudden death fall into class IIb. Beyond these situations the question of 
whether an individual should have an ICD becomes less obvious and warrants a careful 
conversation between patient and cardiologist. This algorithm for ICD indication does not cover 
all personal situations and some individuals who have an increased risk choose not to have an 
ICD, while individuals without clear risk factors sometimes choose to act conservatively and 
have an ICD implanted. 
An ICD is not without side effects. Inappropriate shocks, limitations on lifestyle, 
economic restraints, and self-image issues can be upsetting and may alter quality of life. 
Furthermore, in Thailand where Brugada syndrome is endemic, an ICD is not economically 
feasible for many individuals. As mentioned above there have been many cases of sudden 
cardiac death due to Brugada syndrome as early as infancy. An ICD is not practical for infants or 
young children and remains a difficult decision for parents of older children. 
3.4.4 Medications 
Pharmacological therapy has the potential to rebalance currents, either as an adjuvant to an ICD 
or in the absence of a device. Quinidine, an anti-arrhythmic drug that has potassium channel 
blocking properties has more recently been shown to be an effective preventative measure for 
individuals with an increased risk. Quinidine has been shown to prevent ventricular fibrillation 
induction in patients with Brugada syndrome (Belhassen et al., 2004). It also appears to suppress 
spontaneous arrhythmias. Quinidine has been shown to be effective in individuals who suffer 
 13 
from electrical storms and as an adjuvant therapy in patients with an ICD who have experienced 
multiple shocks (Benito et al., 2008). Clinical trials have proven that in some cases quinidine 
prevents inducible and spontaneous ventricular fibrillation. Oral quinidine can be used to treat 
electrical storms in adults and children with Brugada syndrome. Trials addressing the safety of 
quinidine in children have not been conducted, but if its safety is proven it may become a 
welcome alternative to ICDs in children (Baruteau et at., 2009). Other pharmaceutical 
approaches to therapy have been advanced including β-Adrenergic agonists (isoproterenol) and 
phosphodiesterase inhibitors (cilostazol), which boost calcium channel current (Antzelevitch et 
al., 2006). 
3.4.5 Contraindicated medications and controlled substances 
There is an ever growing list of drugs and medications that are contraindicated in Brugada 
syndrome due to their abilities to trigger an arrhythmia. Individuals with Brugada syndrome 
should avoid acetylcholine, alcohol, cocaine, ergonovine, and certain antiarrhythmics, 
psychotropics and anesthetics. Medications preferably avoided include more antiarrhythmic and 
psychotropic drugs, antianginal drugs, dimenhydrinate (antiemetic agent), edrophonium 
(cholinergic agent), indapamide (diuretic agent), terfanadine/fexofenadine (antihistamine) 
(Postema et al., 2009). Many of these medications are prescribed frequently and without 
consequence in the general population. It is vital for both patient and prescriber to be aware of 
contraindicated medications. 
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3.5 MOLECULAR GENETICS 
Brugada syndrome segregates within families in an autosomal dominant pattern, however the 
condition can also be sporadic. Mutations in seven genes have been associated with Brugada 
syndrome (Hedley et al., 2009).  The first mutations responsible for Brugada syndrome were 
found in the SCN5A gene located at 3p21, which encodes the α subunit of the cardiac sodium 
channel (Chen et al., 1998). SCN5A mutations cause a loss of function in the sodium channel 
current. SCN5A mutations are found in 18-30% of patients with Brugada syndrome and are more 
likely to be found in familial than sporadic cases (Antzelevitch et al., 2005). There is significant 
allelic heterogeneity among SCN5A mutations.  
Mutations in several other genes have been found to cause Brugada syndrome, proving 
the wide genetic heterogeneity of this disease. Some individuals with Brugada syndrome have 
loss of function mutations in the glycerol-3 phosphate dehydrogenase 1-like (GPD1-L) gene 
which causes a decrease in the trafficking of the cardiac sodium channel to the cell surface 
(London et al., 2007).  Mutations causing a loss of function in the cardiac calcium channel have 
also been discovered to cause Brugada syndrome. Loss of function mutations in the alpha 
subunit of cardiac L-type calcium channel (CACNA1C) and the beta-2 subunit of the voltage 
dependent L-type calcium channel (CACNB2) were described in 2007 by Antzelevitch et al.  
The beta-1 subunit of the sodium channel gene SCN5A (SCN1B) was found to be associated 
with Brugada syndrome by Watanabe et al., in 2008.  The role of a malfunction in the 
modulation of outward potassium current due to mutations in the beta subunit to KCND3 
(KCNE3) was found to cause Brugada syndrome by Delpon et al., in 2008. Most recently, 
mutations in the sodium channel subunit beta 3 (SCN3B) was discovered to be pathogenic for 
Brugada syndrome (Hu et al., 2009).  
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3.5.1 Genetic testing 
Genetic testing for Brugada syndrome is available through clinical and research laboratories. 
GeneDx currently offers the most comprehensive mutation panel. It includes 5 of the genes with 
identified pathogenic mutations: SCN5A, GPD1L, CACNA1C, CACNB2, and SCN1B. This 
panel detects 26-41% of mutations in patients with a clinical diagnosis of Brugada syndrome. 
The technical sensitivity is estimated to be 98% by sequence analysis. PGx Health offers testing 
for SCN5A. Insurance for genetic testing through clinical laboratories is covered on a case by 
case basis. In circumstances where insurance coverage is difficult to obtain there are some 
reduced payment options through the main clinical laboratories.  
Research testing is performed through laboratories that conduct research on individuals 
and families with Brugada syndrome. Research testing is typically offered at no cost and is paid 
for by grant funding, either through the National Institute of Health, private funds, or other 
sources. The main caveat of research testing is that it is performed at a research laboratory rather 
than a Clinical Laboratory Improvement Amendments (CLIA) approved laboratory. If testing is 
performed by a research laboratory, the results might not be reported to participants. In studies in 
which testing outcomes are reported there is not typically a timeline for giving results to 
participants. 
For individuals with a history of aborted sudden cardiac death or arrhythmias genetic 
testing can confirm the diagnosis that was clinically diagnosed or suspected (Oliva et al., 2008). 
Genetic testing can also be useful for relatives of clinically diagnosed individuals who are 
unavailable for testing. In such cases, clinical testing can be useful to identify the best candidates 
for genetic testing (i.e. a family member with an abnormal electrocardiogram). Genetic testing 
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for individuals without any symptoms can identify mutations, but can make therapeutic decisions 
confusing. Presymptomatic testing is typically only performed on individuals for whom a family 
mutation has been found. 
Genetic testing is unable to find a mutation in the majority of individuals with Brugada 
syndrome. A recent study in which 179 probands with Brugada syndrome were studied showed 
that 72% were negative for mutations in the known genes associated with the condition (Hu et 
al., 2009). This study highlights the absence of genetic explanation for the majority of Brugada 
syndrome patients, which makes risk identification among family members challenging. 
3.5.2 Overlap of conditions 
As stated above, Brugada syndrome belongs to a category of disorders called channelopathies, 
which are a group of hereditary conditions that cause electrical disturbances in the heart due to 
impaired regulation of cardiac ion currents. Channelopathies include long QT syndrome (LQTS), 
Short QT syndrome, and catecholiminergic polymorphic ventricular tachycardia (CPVT).  
SCN5A mutations have been identified in long QT syndrome type 3, sudden infant death 
syndrome, and in cases in which a combination of arrhythmia and structural heart disease have 
caused sudden death (Hedley et al., 2009). Brugada and long QT syndromes share similar 
symptoms, genetic causes, and psychosocial implications. Although little has been studied on the 
needs and concerns of families with Brugada syndrome, comparisons can be made between the 
two syndromes. Long QT syndrome is arguably better studied, most likely due to its higher 
prevalence (1 in 3,000 to 7,000) and longer recognized history among the medical community.  
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3.6 PSYCHOSOCIAL ASPECTS OF BRUGADA SYNDROME 
Perhaps because Brugada syndrome is a newly described condition, there are few published 
documents evaluating the psychosocial aspects of the condition. Therefore these aspects can be 
looked at individually and applied to the unique case of Brugada syndrome. Overlap with related 
conditions can also be useful in the identification of psychosocial needs. Some of the research 
into the psychosocial effects of long QT syndrome can be used to predict the concerns of 
families with Brugada syndrome. The phenotypic overlap with Arrhythmogenic Right 
Ventricular Dysplasia/Cardiomyopathy can also help identify some of the needs of individuals 
with this type of condition. 
3.6.1 Survival of a sudden death event 
Brugada syndrome is often first diagnosed when there is a sudden cardiac death or an aborted 
sudden cardiac death. The history of a sudden death event impacts the psychological health of 
the individual (in the cases where the death was aborted), the spouse, children, parents, and 
extended relatives. For a surviving individual, studies have shown that a person is at greater risk 
for poor psychological adjustment if they experienced more significant life changes, such as an 
inability to return to work (Sauvé et al., 1995). If survivors and their family are assisted in coping 
with changes from their former lifestyle, then they are more likely to adjust successfully. This 
assistance may come in the form of family and friends, a support group, information provided by 
health care professionals, referrals to therapy, and other informational resources. 
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3.6.2 Living with an increased risk of sudden cardiac death 
Individuals with clinical Brugada syndrome carry a 25% lifetime risk of suffering an 
arrhythmogenic event, which includes sudden cardiac death. Once a person is identified as 
clinically affected, this risk becomes a distinct possibility for that individual. As mentioned 
above, this risk percentage is not likely applicable to women and makes the quantification of 
their risk confusing. The risk of sudden cardiac death  may be the most difficult aspect of the 
condition in terms of coping. It also has implications for spouses, children, siblings, and parents. 
As for individuals who are identified as having a pathogenic mutation, but are clearly not 
clinically affected, their risk for an event is unknown. This adds to the uncertainty involved in 
Brugada syndrome.   
Psychosocial research in long QT syndrome has pinpointed the main causes of concern in 
those patients who must live with an increased risk of sudden cardiac death. The main causes of 
concern were uncertainty, unresolved emotions, and worry for other family members (Andersen 
et al., 2008). Uncertainty stems from a lack of knowledge about the condition, specifically not 
understanding the symptoms and treatment options. The concern of unresolved emotions usually 
originated in previous dramatic events within the family or an anticipation of a future event. 
These causes of concern can also apply to families affected by Brugada syndrome. 
3.6.3 Living with an ICD 
As ICDs are the only proven effective therapy for Brugada syndrome, many affected individuals 
are confronted with the prospect of undergoing implantation. An ICD has pros and cons. An ICD 
is implanted by an operation under constant sedation or general anesthesia in which the device is 
 19 
inserted under the skin of the chest. It provides extraordinary protection and has become a 
relatively routine procedure. An ICD detects slow heart rates (bradyarrhythmia) and fast heart 
rates (tachyarrhythmia) and uses electrical stimulation to treat an abnormal rhythm. Though 
routine, an ICD is not without risks and requires maintenance, meaning further surgeries to 
replace batteries, replace the device itself, or revise the leads. Risks include infection, blood loss, 
and damage to blood vessels or the heart. Having an ICD can place limitations on certain 
occupational activities, such as welding, working around industrial generators, or MRI 
equipment. A shock from the device can be uncomfortable and can occur inappropriately even if 
the device parameters are correct. Psychological distress can be associated with having an ICD. 
Depression and a decreased quality of life have been documented in individuals with ICDs 
(Friedmann et al., 2006). There seems to be general agreement that individuals with an ICD tend 
to benefit from support groups aimed at living with a device. Young adults (ages 18-40) have the 
added concerns of childbearing and childrearing while having an ICD in place (McDonough et 
al., 2009).  
Children are occasionally recommended for ICD, typically when they have had an 
aborted sudden death. Evaluation for ICD therapy in a child is complex. As a child grows they 
will outgrow their device and will need future surgeries. It can also be an ethical dilemma for 
parents who choose to implant a device that can save their child’s life, but will restrict them to a 
lifetime of battery and lead maintenance as well as lifestyle limitations. 
3.6.4 Risk to children 
Symptoms of Brugada syndrome can appear in childhood. Some families have seen multiple 
affected children who suffered sudden death before age 3 (Wilde et al., 2000). 
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Electrocardiograms in children with Brugada syndrome may show a clear type 1 pattern, they 
may be suspicious, or they may be completely normal. Children who show a spontaneous type 1 
ECG pattern appear to be at a higher risk of cardiac events (Probst et al., 2007). An ICD may be 
considered in such cases or it may be recommended that they be watched more closely. Fever is 
the most dangerous risk factor for precipitating an arrhythmogenic event in a child with Brugada 
syndrome (Probst et al., 2007).  Immediate fever reduction is important in any child who is 
known or suspected to have Brugada syndrome. This can cause increased anxiety for parents 
during routine childhood illnesses. 
The exact risk to children is unknown as there are relatively few studies on the risk for a 
cardiac event in children with a known mutation. The scarcity of studies on children also 
translates to an unknown value of the clinical diagnosis parameters as used in adults. An ICD is 
an effective treatment for children with manifestations of Brugada syndrome, though ICD 
surgery in children carries similar risks as in adults, with the added difficulty of frequently 
changing the ICD as the child grows. There are also psychological implications due to body 
image perceptions associated with having an ICD.  
One may ask, how does a parent adjust to the reality that their child is at risk for sudden 
death? Researchers posed the same question to parents of children with long QT syndrome. In 
one study of parents of LQTS patients, 50% of parents who knew their child was a mutation 
carrier for LQTS showed high distress levels. The high level of distress continued in a third of 
those parents 18 months after testing (Hendriks et al., 2005). Implications of this study suggested 
that LQTS families need more support from health care providers to combat the stress of 
everyday living with LQTS. Families with Brugada syndrome likely have similar causes of 
distress. In another study involving LQTS parents, some were unable to handle the fear and 
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uncertainty of the risk for their children and opted to have devices planted in all of their children 
who had mutations (Farnsworth et al., 2006). This may differ slightly in Brugada syndrome 
parents since the prolonged QT is often observed at a younger age in LQTS patients than the 
Brugada sign is observed by ECG in younger Brugada patients.  The same study showed that 
parents wanted more knowledgeable health care providers who they could trust with their 
children’s care. Many participants commented on their frustration towards providers who had 
dismissed symptoms in children, which in some cases resulted in a child’s death. 
Children may or may not be told about their risks, depending on parental decisions. This 
is another ethical dilemma that parents face as they balance the benefit of informing their 
children about the signs to be aware of with the worry of causing distress and anxiety. In cases 
where children are aware of their risk they may benefit from speaking with a child psychologist. 
3.6.5 Presymptomatic genetic testing 
In a study investigating genetic testing in kinships with familial dilated cardiomyopathy, the 
authors suggested that explaining the complexities of presymptomatic genetic testing needs close 
attention by those ordering the testing (Hanson et al., 2001). The authors suggested a team 
approach, utilizing a cardiologist, genetic counselor, and a geneticist.  
In a recent article in Cardiology in which Oliva et al., examine the clinical heterogeneity 
of channelopathies, including Brugada syndrome, the authors ask “what does it mean to be an 
asymptomatic carrier of a mutation linked to malignant arrhythmias?” (Oliva et al., 2008). The 
authors cite the uncertainty of clinical phenotype in the presence of a mutation and emphasize 
the use of a known mutation as a risk factor rather than a predictor of sudden death. Other 
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parameters (ECG, drug challenge testing, and programmed electrical stimulation) must guide 
risk stratification and therapy. 
3.6.6 Difficulties understanding the condition 
In families in which presymptomatic genetic testing has been performed, the difference between 
a clinical and genetic diagnosis can be difficult to grasp. While some members of the family 
carry a clinical diagnosis based on symptoms and electrocardiogram pattern, others may have 
discovered their risk based on presymptomatic genetic testing. Diagnosis of the condition cannot 
be based on mutation alone. In the case of a known mutation, diagnosis still depends on clinical 
criteria. Some mutation carriers will have mild symptoms that would not have led to a diagnosis 
outside of mutation testing, but could indicate an increased risk. Others may never develop 
symptoms. Understanding the difference between having the syndrome because one has 
symptoms versus having the syndrome because one carries a genetic mutation is complicated 
especially in families where there is a heterogeneous mixture of clinically affected and clinically 
unaffected mutation positive individuals. The uncertainty involved in various aspects of Brugada 
syndrome is one of the most difficult obstacles for health care professionals and patients.  
3.6.7 Attitudes towards research 
Families with a genetic condition are often approached for participation in genetic research. 
Reasons for participating in research include a desire to obtain knowledge that can be personally 
beneficial and helpful for family members, to reduce uncertainty, to aid in future decision-
making, to contribute to scientific advancement specific to their condition, and trust in the 
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researchers (Laegsgaard et al., 2009; Lerman et al., 2002; Connell et al., 2001). Reasons that 
individuals decline participation in genetic research include a lack of desire for information if 
treatment is uncertain, fear of negative side effects of testing, distrust or skepticism of research, 
and possible stigma associated with a condition (Laegsgaard et al., 2009; Connell et al., 2001). 
The attitudes towards genetic research can vary within a family.  
Research testing can be more convenient and economical for families; however it can 
cause several concerns to arise. Individuals may be concerned about privacy or they may decide 
years into the research that they have changed their mind and no longer wish to participate.  
Tension can arise when some family members decide to participate and others refuse. When 
searching for a genetic explanation in cases where a proband tests negative for all of the known 
mutations, it is most helpful to include as many family members as possible to improve the 
chance of finding the causative gene through linkage analysis. Families often understand the 
benefit of including as many members as possible in a linkage study and may apply pressure on 
unwilling family members. Research involves an open line of communication amongst family 
members as to why they are being asked to participate. This can lead to blame of the first 
affected person in the family for bringing the knowledge of the condition upon the rest of the 
family (Arribas-Ayllon et al., 2008). Fear of insurance discrimination based on clinical or genetic 
status can also inhibit research participation.  
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3.7 CURRENT AVAILABLE RESOURCES 
3.7.1 Websites 
Once a diagnosis is made, the internet is often the first resource that a person explores for 
answers. An internet search of “Brugada syndrome” returns results of publicly available medical 
websites, including eMedicine, Genetics Home Reference, MayoClinic.com, WrongDiagnosis, 
GeneReviews, and OMIM.  A full GeneReviews entry for Brugada syndrome did not exist at the 
time of this project. The same search reveals www.brugadadrugs.org and www.brugada.org, two 
sites operated by the Ramon Brugada Senior Foundation. The latter of these sites contains the 
most useful information for patients, including explanations of the condition and a forum for 
discussion. 
Several clinical laboratories also offer helpful information on Brugada syndrome for 
patients. These resources are accessible by patients and health care professionals through 
GeneDx at: http://www.genedx.com/ext_upload_files/patients_guide_brugada_syndrome.pdf and 
through PGx Health at http://www.pgxhealth.com/familion/patients/. 
The most up to date and comprehensive list of contraindicated medications is publicly 
available at www.brugadadrugs.org (Postema et al., 2009). The website is designed for medical 
professionals, but can be accessed by anyone. It compiles journal articles citing the 
contraindication of specific medications and controlled substances. It is organized by the strength 
of research behind each contraindication into the categories “drugs to be avoided by Brugada 
syndrome patients” and “drugs preferably avoided by Brugada syndrome patients.” The website 
also contains a patient letter to health care professionals listing the prescriptions that individuals 
are advised against taking.  
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3.7.2 Research articles 
Research articles pertaining to Brugada syndrome are accessible through Google and PubMed, 
although a subscription is often required to view the full text. Public and academic libraries have 
subscriptions to some of the journals that publish research on Brugada syndrome. Many of the 
articles are difficult to comprehend without some training in medical terminology. 
3.7.3 Support groups 
Due to the rarity of Brugada syndrome, the internet is the most comprehensive resource for 
support, especially for individuals outside of urban settings. Several online support groups exist, 
though some are for overall channelopathies or general conditions involving sudden cardiac 
death or arrhythmias. The Brugada Foundation provides a support group on their website in the 
form of a discussion board. The discussion board is moderated by doctors associated with the 
foundation and is available in English and Spanish. This support group is located at 
http://www.brugada.org/support_group/viewforum.php?f=4. The board is divided into postings 
such as frequently asked questions, list of doctors, personal stories, medication and treatments, 
and issues with children. The C.A.R.E. Foundation (Cardiac Arrhythmias Research and 
Education Foundation, Inc.), is located at http://www.longqt.org/ and the SADS Foundation: 
Sudden Arrhythmia Death Syndromes is located at http://www.sads.org/. These foundations 
include information and some opportunities to contact other individuals with similar conditions. 
ICD support and informational groups exist through independent websites, through ICD 
manufacturers, and through local hospitals and community groups. Though these foundations are 
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professionally operated, discussion boards and general online sources of information are 
naturally susceptible to misinformation and speculation. 
3.8 DEVELOPMENT OF AN EDUCATIONAL RESOURCE 
Written health information is a common addition to patient care. Pamphlets, brochures, fact 
sheets, and guides are often found in doctor’s offices, hospitals, libraries, schools, and 
community centers. Their general purpose is to provide information on specific health topics. 
Genetic counselors often develop educational resources for genetic conditions that can help a 
person understand their diagnosis and its implications.  
There has been much discourse on the design of education modules. Originally patient 
information modules were designed with the goal of patient education. The “patient education” 
discourse assumes at least some patient incompetence and designs the written material to bring 
the patient’s knowledge about a condition in line with what is medically correct (Dixon-Woods, 
2001). This type of design will convey important medical information, but often in a paternalistic 
manner that may lack emphasis of patient autonomy in places where it would be appropriate. 
This represents the majority of patient information materials. The “patient empowerment” 
discourse has different aims. In this discourse a patient is considered an active participant in the 
written consultation and the patient’s interests, needs, and priorities are considered over those of 
health care professionals. The idea that a patient cannot cope with unpleasant information is 
exchanged for presenting potentially unpleasant information along with the tools to best 
understand and cope with that information: “The patient empowerment discourse accepts that 
patients may well have difficulties in understanding and remembering medical information, but 
 27 
sees printed information as a means of empowering them rather than correcting them” (Dixon-
Woods, 2001). In the “patient empowerment” discourse the patient or, “the imagined reader” 
should remain consistent throughout the resource. This discourse also recommends a non-
paternalistic approach, as is consistent with the non-directive ethos of genetic counseling. It also 
recommends the disclosure of uncertainties about a condition, which is especially appropriate for 
Brugada syndrome. 
Genetic counselors can elicit information from their patient population to help determine 
the content and design in order to create a tailored educational resource. Within the field of 
genetic counseling there has been discourse on the importance of evaluating the audience for the 
creation of educational materials: “Knowledge about the target audience is crucial to producing 
informational materials on genetic conditions” (Baker et al., 1998). Questionnaires are an 
effective tool for the evaluation of the target audience. In a study that analyzed how LQTS 
patients cope with risk, the authors found that the participants desired more information about 
their condition. Some participants suggested a gradual stream of information so that it could be 
absorbed slowly (Andersen et al., 2008).  A gradual stream of information can be accomplished 
through repeat contact with health care professionals or through a series of informational 
resources that build-up in informational output so a patient has time to absorb the information. 
There is a general consensus in published literature about the visual design and format of 
educational resources to aid in the comprehension of the material. These features include: 
accurate and up-to-date content, a clear conversational style preferably written as questions and 
answers, organization of categories within the resource, consideration of the needs of the target 
audience, attention to the reading level of the audience, attention to the complexity of concepts, 
definitions for necessary medical terminology, adequate spacing and easy to read typefaces to 
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reduce eye fatigue, short concise sentence structure with clear logic, use of summary sections to 
emphasize important points, use of boldface or underline techniques for the most important 
points, use of labeled illustrations where appropriate, attention to color, and feedback (Hussey, 
1997; Vahabi et al., 1995). Recommendations for improved readability include: giving key 
information in bold or italics, using common, specific words and short sentences, giving 
examples to explain uncommon words or concepts, and engaging the reader (D’Allesandro et al., 
2001). The average reading level of adults in the United States is between the fifth and eight 
grade levels (Vahabi et al., 1995). The Flesch-Kincaid Grade Level uses a formula that calculates 
mean sentence and word length to determine readability. Microsoft Word incorporates the 
Flesch-Kincaid Grade Level test to determine the approximate grade level readability of text 
(D’Alessandro et al., 2001). 
There are multiple patient materials available as models. “Implantable Cardioverter-
Defibrillators (ICDs), A Patient’s Guide,” written by Emmanuel Horovitz and published by 
HeartWise Patient Education Series is a 30 page guide to ICDs. It is written in question and 
answer format, with important terms in bold. It includes sections that are easy to navigate and 
has appropriate images that help the reader visualize the concepts. It addresses medical terms, 
procedures, and concerns, as well the psychosocial implications of living with an ICD. 
“Arrhythmogenic Right Ventricular Cardiomyopathy, An Information Booklet for Patients and 
Their Families” was written by Dr. Kate Houston for the Canadian Sudden Arrhythmia Death 
Syndromes (SADS) Foundation. It is also written in question and answer format with clear 
explanations of tests. It begins with a letter to the patient and a table of contents. Quotes from 
patients are dispersed throughout the booklet (where applicable) to provide a sense of connection 
between the author and the reader. Another example is “Now that you’ve been told your baby 
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has a congenital heart defect” a booklet written by Beverly Tenenholz and published by the 
National Society of Genetic Counselors. This resource uses bold lettering to point out key terms 
and it uses simple language to explain complex conditions. It includes a glossary, basic black and 
white images that clearly depict the heart defects, and similar to the SADS booklet it 
incorporates quotes from individuals who have been through the same type of diagnosis. 
The motivation behind this project stemmed from an observed need for easily accessible 
wide-ranging information for families with Brugada syndrome as “comprehensible information 
can motivate some people to seek more knowledge about even frightening and uncomfortable 
health topics” (Vahabi et al., 1995). The utilization of design recommendations in a manner that 
enables patient empowerment would be expected to create a better educational resource. As 
eloquently stated in A Guide to Genetic Counseling, concerning the intention of patient material 
design, “to place more power into the hands of individuals and their families affected by genetic 
disease is to be sure that they have adequate knowledge—not just information—about their 
genetic circumstance” (Baker et al., 1998). It is the intention of this project to focus on the needs 
of families with Brugada syndrome to provide the tools for understanding and coping. 
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4.0  MATERIALS AND METHODS 
4.1 DATA COLLECTION 
4.1.1 Participant recruitment 
The families included in this project are enrolled in Familial Studies in Cardiovascular Disease at 
the University of Pittsburgh, IRB #960619. The principle investigator is Barry London, M.D., 
Ph.D., Professor of Medicine at the University of Pittsburgh Medical School and Chief of 
Cardiology at the University of Pittsburgh Medical Center. This study is funded by a grant 
through the National Institutes of Health. Familial Studies in Cardiovascular Disease enrolls 
families who have at least one affected individual with an inherited cardiovascular condition, 
such as Brugada syndrome. The aim of that study is to identify at risk individuals and novel 
causative genes.  
For this project individuals from families with Brugada syndrome were contacted and 
asked if they would like to participate. Participation involved informed consent and the 
completion of a questionnaire. The addendum consent form for this project can be found in 
Appendix A.  Participants were informed that their results and comments would be used in the 
creation of educational material on Brugada syndrome. Questionnaires and consent forms were 
mailed or emailed to the individuals who agreed to participate. Their participation was not linked 
 31 
to any of their medical or genetic information in the Familial Studies in Cardiovascular Disease. 
There was no compensation for participation. Eleven individuals agreed to participate and ten of 
the eleven questionnaires were returned. 
4.1.2 Questionnaire 
A questionnaire was developed to obtain useful information from individuals who have 
experience with Brugada syndrome. This document can be found in Appendix B. The 
questionnaire was divided into four sections: 
I.  Understanding of Brugada syndrome: 
The questions in this section were designed to qualify the general 
understanding of Brugada syndrome features, inheritance patterns, risk 
factors, and treatment.  
II.  Personal experiences: 
These questions asked the participant to respond based on their personal 
experience. 
III. Areas of difficulty: 
This section listed terms and concepts associated with Brugada syndrome 
and asked the participant to identify any that they did not fully understand. 
IV.  Open-ended questions: 
These questions prompted the participant to describe their experiences, 
concerns, and provide insight through their own words. 
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4.1.3 Demographic information 
Demographic information was obtained through a short survey preceding the questionnaire. 
Demographic information included age range, gender, marital status, number of children, highest 
level of education, whether or not the participant has Brugada syndrome, and if they have 
relatives with Brugada syndrome. All identifiable information was excluded and individual 
participation was kept anonymous and separate from their participation in the Familial Studies in 
Cardiovascular Disease research. 
4.1.4 Development of an educational module 
The process for developing an educational module for a health condition involves tailoring 
important facts about the condition to the expected audience and utilizing a format that is 
accessible. The basic components of information about a genetic condition are: a description of 
the condition including the signs and symptoms, how a diagnosis is made, the genetic cause, a 
description of the inheritance pattern which includes specific risks to other family members, the 
treatment options, potential risk factors, available support resources, and further resources for 
more information.  
The design of an educational module depends on its audience, the topic, and the resources 
available. The audience for this module is families who have been given a diagnosis of Brugada 
syndrome. The audience profile consists mainly of adults with some higher education, but little 
or no medical training. A concise yet conversational style uses question and answer formatting 
and categorization of important topics. This allows the reader to skip to certain topics that may 
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be applicable to them at a certain time. The guide is not designed to be read in one sitting. The 
information used to create the guide was from the most recent publications on the condition.  
The goal for reading level maximum was grade 8. To determine reading level the 
readability option in Microsoft Word was utilized. An attempt was made to limit answers to short 
sentences within brief paragraphs that express one idea at a time. Typeface was chosen based on 
its spacing and clarity in order to reduce potential eye fatigue. Extra spacing was added between 
each question in order to reduce eye strain and enable easy maneuvering between questions. 
Basic illustrations were included if available and appropriate. The PDF format allows the guide 
to be easily printed for patients and accessible on the internet. 
Pilot testing to gather patient feedback will be performed before final drafts are 
completed and distributed. The product of this project is designed to be malleable so that it can 
be updated with new information, such as genetic discoveries and therapeutic options. 
4.2 DATA ANALYSIS 
4.2.1 Identification of strengths and weaknesses 
Due to the small sample size used in this project statistical analysis of the answers to the 
questions was limited and not required for the goals of this project. Instead, the responses to the 
questionnaire regarding understanding of the condition were tallied to capture apparent strengths 
and weaknesses. Terms and concepts that were designated by the participant as confusing were 
automatically incorporated into the module with definitions and explanations. 
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4.2.2 Personal insight 
The open-ended questions provided personal insight that highlighted some strengths and 
weaknesses in understanding, but also enlightened the author to points of stress caused by the 
condition that could be addressed in the resources. 
 35 
5.0  RESULTS 
5.1 CHARACTERIZATION OF THE SAMPLE 
The project involved ten participants, five men and five women from a total of four families with 
Brugada syndrome. All members are married and either have children or their partner is 
pregnant. Six have Brugada syndrome, one is not sure if they have Brugada syndrome, and three 
are unaffected spouses. Ages range from mid-20s to mid-70s. All participants have close 
relatives with Brugada syndrome. Highest levels of education range from high school to graduate 
training. 
5.2 SPECIFIC AIM 1: IDENTIFIABLE NEEDS 
The apparent strengths based on the general knowledge questions included consistent 
understanding about the cause of events in Brugada syndrome and the use of an ICD to treat 
abnormal rhythms. Most could identify some of the risk factors associated with syncope and 
sudden cardiac death. Most participants understood that their children have a 50% chance of 
inheriting the condition.  
Areas of weakness included little knowledge about contraindicated medications shown in 
consistent responses to multiple questions on this topic. Most were not aware of any precautions 
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to lower risks such as avoiding certain medications, avoiding excessive alcohol intake, avoiding 
hyperthermia, and promptly treating fever. There were some false beliefs about exercise 
triggering events and some confusion about Brugada syndrome causing heart disease, such as 
coronary heart disease. Only one person was able to identify the chance that a person with 
clinically diagnosed Brugada syndrome would experience an event (approximately 25%). 
In the personal experience section of the questionnaire individuals were asked questions 
about how they dealt with Brugada syndrome. Most stated that they had used the internet as a 
resource when researching the condition, while some relied solely on their doctor and family 
members for information. Approximately half spoke with a genetic counselor before testing. 
Almost everyone had their genetic testing results explained to them (most commonly by a 
cardiologist). Some were unsure what their genetic testing results meant for them and for their 
children. About half said that genetic testing had caused them some anxiety. Unaffected 
participants denied feelings of survivor guilt due to negative presymptomatic testing and 
participants with the condition denied feelings of resentment towards those individuals in the 
family who did not inherit the condition.  When asked who they told about the condition, the 
most common answers were close family members, close doctors, and close friends. Few said 
that they told coworkers and no one claimed to tell a clergy member. Surprisingly, the majority 
of participants said that they had not sought out a support group, though some indicated they 
thought they would benefit from talking to other families with Brugada syndrome. It is important 
to note that many of the participants are members of large families in which Brugada syndrome 
is prevalent and there is reliance among family members who also understand the condition. 
There were some claims that family relationships changed based on the diagnosis of 
Brugada syndrome. For many people their relationships became closer, while some stated that 
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tension arose among family members and the diagnosis was a source of strain on these 
relationships. The greatest obstacles to coping with the diagnosis were the knowledge that other 
family members may also be affected, anxiety, trusting others with personal information, and 
lifestyle changes due to an ICD. The decision to test children caused anxiety and stress, as well 
as relief in some cases. Almost all of the participants stated they decided to participate in 
research to find answers, to find a genetic cause in the family, to help other families, to help find 
a treatment, and to know which individuals to watch closely for symptoms.  
The third section of the questionnaire listed terms and concepts associated with Brugada 
syndrome and allowed the respondent to identify any that were unclear or that they would like to 
understand better. The selected terms and concepts included: the genetic basis of Brugada 
syndrome, treatment, risk for other family members, symptoms, syncope, EP study, genetic 
testing, and ventricular arrhythmia. Few understood the meaning of autosomal dominance, 
though half claimed that they would be able to explain how Brugada syndrome runs in families 
to someone else. Most said that they understood the risk to their children.  
The final section of the questionnaire asked for personal perspective on certain topics. 
The first question asked about satisfaction in the explanation of the condition that they initially 
received. The comments included, “detail is confusing,” they “had to do [their] own research,” 
and the “lack of satisfaction came from no available literature…it was overwhelming at first.” 
Another question asked about presymptomatic testing in the family and how it affected their 
families. The common responses to this question revealed anxiety due to wondering who is at 
risk, many questions from other family members, blame from other family members and overall 
stress in the family. A question about the impact of genetic testing results revealed in one family 
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that it “caused some change in openness, worry about kids, grandkids” and “anger when some 
[family members] would not participate” in genetic and clinical testing.  
All of the parents in the study felt it was appropriate to have their children genetically 
tested and monitored by electrocardiogram. Most stated that they did not talk about the condition 
with children under 10 and for those children under 18 who knew something about the condition 
the parents simply explained that there is safety in knowing what signs to look out for and that it 
is something that affects other family members. One parent commented, “I would advise parents 
of young children to say little or nothing even in front of them. Older children only that there is a 
concern and they should tell parent if fainting, fast heartbeat, etc.” Another participant advised, 
“I guess the only thing to explain it is for them to think about all of the good 
things that you did inherit from your family, not this one thing that isn’t perfect. It 
certainly is better than other physical ailments that also might be passed down, or 
other ailments that you could have. It certainly isn’t ideal, but it could definitely 
be worse and it definitely isn’t your fault.”  
 
When asked how one adjusts to the idea that their child might be at risk for sudden death, 
answers included prayer, genetic testing that allowed them to know who to carefully monitor and 
who was not at risk, turning shock into being grateful that they were given a second chance, and 
trying not to worry. Concerning their adjustment one parent simply commented, “not well.” 
Participants advised that post diagnosis one should make lists of questions and concerns 
and periodically call their doctor. Since many of these individuals received their diagnosis 
through the Familial Studies in Cardiovascular Disease, it is not surprising that they found the 
ability to call the investigators in the study to ask questions very helpful. One person commented 
that it would have been helpful to understand why some of their family members feared knowing 
whether they had the condition and why some worried about insurance and legal repercussions. 
There was a general consensus that the more information that could be provided, the better. 
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Specifically, “what does it mean in terms or work, life, recreation, etc” and “how it affects 
children and recommendations of the next few steps” were information of high value. Support 
from medical professionals was either badly needed or much appreciated depending on the 
personal situations. 
5.3 SPECIFIC AIM 2: CREATION OF AN EDUCATIONAL RESOURCE 
The results of the second specific aim can be found in Appendix C and Appendix D of this 
document. 
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6.0  DISCUSSION 
6.1 SPECIFIC AIM 1 
An understanding of risk factors and precautions that can lower risk is a vital part of medical 
management. When diagnosed with a condition, individuals would benefit from receiving 
information that enhances the likelihood of engaging in behavior that allows them to best protect 
themselves and their families. Brugada syndrome cannot yet be cured, but there are defined steps 
that can be taken to lower the chance of a deadly event. The comprehensive list of 
contraindicated medications is somewhat recent, so it is not surprising that individuals were 
unaware of its extent or even its existence. Novel as it may be, this research can and should be 
quickly translated into patient information. The list of contraindicated medications contains 
many common prescriptions that seem harmless and therefore it is important that the patient and 
their physicians are familiar with this list. For example, children are less likely to have an event 
than their adult counterparts, but a seemingly helpful medication for a separate condition could 
increase their risk and potentially trigger an arrhythmia. At this institution the list is addressed by 
the cardiologist who diagnoses the condition, but it is unknown if this it the case in all settings. 
Whether that information is retained by the individual and passed on to other family members is 
also unknown. The knowledge of precautions is vital and needs to be presented with an emphasis 
on sharing the information with all of one’s doctors and family members. 
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As with any condition it is possible for false beliefs to arise, often due to confusion. 
Brugada syndrome is a cardiac condition and thus it is not surprising that there is some 
misunderstanding about its links to the more commonly known heart diseases. The types of heart 
disease that cause heart failure or heart attacks are prevalent and well-known in the general 
public thus it is easy to assume since Brugada syndrome has an effect on the heart it is similar. It 
is important to understand the separation between Brugada syndrome and other types of heart 
disease so that one does not confuse the risk factors and precautions for coronary heart disease 
with those specific to Brugada syndrome. It is also important so that a person can relay accurate 
information to family members and understand their true risks (which may be greater or lesser 
with Brugada syndrome compared to other types of heart disease). 
Some other arrhythmia conditions such as CPVT, do in fact consist of exercise and 
excitement triggered events. It is important to differentiate for two reasons: so that individuals 
with Brugada syndrome know what the real risk factors are and do not place unnecessary 
limitations on their lifestyle. States of overexcitement or exercising vigorously have not been 
shown to be legitimate risks for individuals with Brugada syndrome and therefore these should 
not add to their concerns. The chance that someone clinically diagnosed Brugada syndrome will 
experience an event (i.e. fainting or sudden cardiac death) is approximately 25%. This is possibly 
an overestimate since the true prevalence of Brugada syndrome is unknown. It is also skewed by 
the gender imbalance (a woman’s lifetime risk is most likely not as high as 25%). In spite of the 
uncertainties it is still worth conveying this information to individuals so that they know that 
there is a real risk, but it is not a 100% chance that they will have an event. This knowledge may 
impact a person’s ability to cope with the condition. 
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As expected, most participants used the internet as a resource, while some looked to their 
doctor and family members. A printed guide that is also available on the internet would be 
helpful to this population because it would be searchable on the web and print copies could be 
handed out by doctors and shared among family members. The fact that only half spoke with a 
genetic counselor is not surprising since cardiovascular genetic counseling is a relatively new 
practice area and most of the participants obtained genetic testing through a research study. 
Participants’ responses indicated that some were unsure of the meaning of their results, which 
suggests that genetic counseling could be beneficial for individuals with Brugada syndrome. For 
this reason, the resource will contain information about finding a genetic counselor and why it 
would be beneficial. The resource needs to address the obstacles to coping with the diagnosis 
that were revealed by the responses: knowing other family members might be affected, anxiety, 
trusting others with personal information, lifestyle changes due to an ICD, and testing children. 
Genetic counseling could enhance individuals’ coping by assisting them in overcoming these 
obstacles.  
The selected terms and concepts included in the questionnaire will be specifically 
outlined and defined in the module. The answers to the third portion of the questionnaire led to 
the decision to create a glossary of terms. The responses to open-ended questions in the 
questionnaire emphasized the need for more information, more help with understanding the 
condition, and more help with coping and handling the anxiety caused by Brugada syndrome. 
For example, it would be appropriate to explain why some family members may not want to be 
tested and explain potential legal or insurance worries. A section on how to talk to children about 
the condition is included because it appears to be a main source of stress. A section offers advice 
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from other individuals. Since participants stated that knowing what steps would come next and 
how it would affect them was either beneficial or needed, this will also be addressed. 
6.2 SPECIFIC AIM 2 
The results of the first aim helped guide the development of an educational resource for 
individuals and families with Brugada syndrome. The outline of the resource was determined by 
background research on education module development and Brugada syndrome along with the 
information gained from participant responses. The strengths and weaknesses observed in the 
questionnaire responses determined which areas to emphasize in the educational resources, such 
as explanations of genetic basis and genetic testing. The terms determined to be difficult to 
understand by respondents were used to create a glossary. Responses to the personal experience 
section of the questionnaire led to an expanded section on children, a section on what to expect 
immediately following a diagnosis, identification of support resources, and explanations of 
clinical testing. The goals for format, visual design, and content were determined prior to the 
creation of this module, but as described below they evolved as the project progressed to create a 
better product, 
Based on the results of the questionnaire and studies on long QT syndrome it is apparent 
that individuals need information, but that information can be very overwhelming. In light of a 
need for a more accessible gradual stream of information the decision was made to create two 
coordinating materials: a basic pamphlet and an in-depth guide. The finding that most individuals 
gained their information from their doctors and tried to use the internet for information 
reinforced the plan to use a PDF format, a file type created by Adobe Acrobat. This format 
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allows the guide and pamphlet to be uploaded onto websites as well as easily downloaded and 
printed for use as patient handouts. It can also be easily updated. The guide and pamphlet will 
initially be uploaded at www.heartgenes.org, a website operated by the Cardiovascular Program 
of Ferre Institute, Inc.  
The visual design goals of this project were accessibility, visual ease to reduce eye strain, 
and well-labeled illustrations. These goals were accomplished through the following steps. Both 
the pamphlet and guide use a conversational question and answer format to keep each segment of 
information accessible. Page numbers were included in the guide for easy navigation. The font 
Century Gothic was chosen subjectively for its readability and clarity as compared to other 
common fonts such as Times New Roman or Ariel. It also provides more spacing then other 
fonts. A font size of 14 was used to further reduce eye fatigue and to assist readers who have 
difficulty with normal size print. The readability Flesch-Kincaid Grade level formula in 
Microsoft Word was used to calculate the estimated reading level. The estimate for the guide was 
grade 8 and the estimate for the pamphlet was grade 7.5. Both of these meet the goal of Grade 5 
to Grade 8 reading level. The longer more complex words that are naturally part of the 
explanations for Brugada syndrome undoubtedly increased the reading level towards the Grade 8 
level. This was alleviated by explaining each complex word in the context of the guide. Key 
terms were placed in bold lettering to emphasize their importance. Illustrations were created to 
explain an ICD, the path from cell to DNA to gene to cardiac muscle, how a gene mutation 
causes an arrhythmia and why this can be tested through blood. All illustrations were drawn by 
the author to avoid copyright issues and each contains labels to elucidate the image. 
This project’s goal of patient empowerment sought not to tell the reader this is exactly 
what you should know or have to do, it sought to show them this is what we know so far about 
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this condition and here are some tools to help understand it better and cope with it. This guide 
can be used as little or as much as needed. A paternalistic tone and directive approach were 
purposefully avoided. In some cases however, a directive statement was made to emphasize the 
recommendation of medical professionals. One example is cocaine: 
Are there any other drugs that increase risk? 
Cocaine has been proven to provoke a life-threatening rhythm 
in persons with Brugada syndrome and should be avoided. 
 
In this statement the phrase “should” was used because the fact that cocaine is an illegal drug 
that can cause sudden cardiac death in patients with Brugada syndrome is well-established. 
Another example is how the guide addresses fever in children with Brugada syndrome. The 
guide states “If they have a fever it needs to be treated as soon as possible because we know that 
fever is the most common trigger of events in kids with Brugada syndrome.” In this case the 
approach is directive because this is another well-established fact and has the potential to be life-
saving medical information for child and parent.  
The guide reveals uncertainties such as therapeutic medications under investigation and 
the fact that the majority of genetic causes have not been identified yet and therefore genetic 
testing is imperfect. Rather than confuse the reader this helps explain why they cannot simply go 
to the pharmacy and get a medication for Brugada syndrome or why they still have the condition 
even though their genetic testing result came back negative. Difficult topics are addressed, such 
as how parents can handle the fact that their children are at risk for sudden cardiac death. The 
patient education discourse would tend to avoid uncomfortable or frightening topics, but this 
approach gives the parent anticipatory guidance. It presents this fact that children are at risk and 
addresses the need for a coping strategy. 
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The content of the pamphlet was limited to a front and back tri-fold design. The same 
format of question and answer conversation in a size 14 Century Gothic font was used in the 
pamphlet. It addresses a few common questions that arise after a diagnosis: “What is Brugada 
syndrome?” “What are the health risks?” “How do I know if I have it?” “What kind of testing 
will I have?” “What causes Brugada syndrome?” “What kind of treatment is available?” “Can I 
lower my risks?” “What are the risks to my children?” “What do I tell my family and friends?” 
and “Who can I talk to?” These questions briefly address each section of the guide.  It also 
directs the reader to two sources of further information, the guide and the Ramon Brugada Senior 
Foundation. The goal of the pamphlet is to provide a quick summary of common questions about 
the condition that can help someone understand it when they may not be ready for more detailed 
information. It can also be useful to use as a visual when explaining the condition to friends and 
family. 
The content of Brugada syndrome: A Guide for Families was arranged by category. A 
table of contents identifies the main categories: “What to expect,” “Symptoms and Diagnosis,” 
“Children,” “Treatment,” “Genes and Inheritance,” “Genetic Testing,” “Support,” a “Glossary of 
terms,” and “Tips from other individuals with Brugada syndrome.” The table of contents 
identifies each category by page number so that the reader can easily access the desired topic. 
“What to expect” consists of a brief snapshot of the initial testing for the individual and other 
family members, possible surgery, potential lifestyle changes, and plans for future monitoring. 
These are worth mentioning early in the guide because they are the initial aspects of diagnosing 
and managing the condition that a person will encounter.  
The section “Symptoms and Diagnosis” explains the symptoms and what causes them. It 
gives the risk (in percentage format) that a person will experience a symptom and discusses why 
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some people in a family may never show signs of the condition. It also explains sudden cardiac 
death since this is the greatest concern for individuals with Brugada syndrome. The various tests 
that a person may have when the doctor is trying to diagnose Brugada syndrome are listed with 
clear explanations. The differences between Brugada syndrome and heart disease are outlined 
and the importance but difficulty of risk stratification is highlighted. The section on “Children” 
addresses their risk, what kind of testing they can have, what to expect in terms of management 
if they do have Brugada syndrome, and the option of prenatal testing. Fever is specifically 
addressed as a risk factor for children. There is also a segment identifying potential concerns for 
addressing Brugada syndrome in children. It includes how to talk to children about the condition 
and how other parents have handled this situation. The answers to these questions were based on 
the responses from the participants in the questionnaire. 
The “Treatment” section begins with an explanation of ICDs, their risks and benefits, the 
prospect of multiple future surgeries, and lifestyle changes. An illustration of an ICD as it is 
situated in a heart is provided for clarity. Potential therapeutic medications are discussed. 
Precautions are listed, including contraindicated medications, alcohol, and cocaine, along with 
instructions on how to access the Brugada Drugs website. Lifelong monitoring is also explained. 
The sections on “Genes and Inheritance” and “Genetic Testing” are fittingly the most 
complex sections, but they have been broken down to make the concepts accessible. Genes and 
mutations are explained with the aid of illustrations. How a mutation occurs is addressed along 
with the fact that there need not be any blame associated with it.  The decision to use the term 
“mutation” rather than “gene change” was made because the available literature on most genetic 
conditions uses “mutation” and if a person has genetic testing they may be familiar with term 
“mutation.” Alternation with the phrase “gene change” may be confusing. In contrast, terms such 
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as “abnormal” or “bad” (when explaining a type of rhythm) were exchanged for “irregular,” 
“unusual,” or “life-threatening.”  
This section also explains how Brugada syndrome is inherited and specifically addresses 
the risks for parents, siblings, and children. The “Genetic Testing” section explains the process 
of genetic testing and the reasons why some people choose to have it. It covers the accuracy and 
limitations of genetic testing, insurance coverage, and insurance discrimination. The role of a 
genetic counselor is explained and information is provided to direct the reader to the webpage of 
the  National Society of Genetic Counselors, where they can use a tool called “Find a Counselor” 
to locate local genetic counselors. This section also addresses the differentiation between 
unaffected and affected individuals who are mutation positive. Research genetic testing is 
covered and differentiated from clinical genetic testing. Since the participants indicated that it 
would have been helpful to understand why some family members did not want to participate in 
testing this matter is specifically discussed. 
The “Support” section covers who to talk to about the condition and available support 
groups. It addresses the concerns of trusting others with personal information and finding reliable 
information on the internet. A list of professional websites is included. The final sections are a 
Glossary, which covers many terms and concepts related to Brugada syndrome including those 
specifically indicated as confusing by the questionnaire participants, and a section containing 
advice from other individuals with Brugada syndrome.  
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6.3 IMPLICATIONS 
This project has shown that the informational needs of patients with Brugada syndrome are 
complex, deep and are not currently being met mainly due to the novelty of the condition. Access 
to health care professionals, careful explanation of the condition and supplementation of 
information resources are integral to meeting these needs. The results of this project, a two-part 
educational resource, can be used to aid in the explanation of the condition and provide extended 
patient-friendly information to meet the needs of these individuals and their families. This 
highlights the important roles of genetic counselors in counseling for arrhythmia conditions and 
utilizing patient feedback to create educational resources. 
6.4 LIMITATIONS AND FUTURE DIRECTIONS 
6.4.1 Limitations of the study 
All of the individuals who participated in this study are enrolled in a research study through 
which they have already been educated about the condition. This may be reflected in their overall 
knowledge on the general information about the condition. Many of the individuals have 
extensive support systems in their families and may not encounter the kind of psychosocial 
obstacles that others coping with Brugada syndrome might face. Many of them have also been 
diagnosed by a cardiologist highly familiar with Brugada syndrome and received more 
information at their diagnosis and post-diagnosis then others with the condition may have 
received. 
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This study was a project intended to aid in the development of an educational resource 
rather than qualitatively or quantitatively analyze the strengths, weakness, or psychosocial 
implications within the population of individuals with Brugada syndrome. A more thorough 
study with a larger sample size would be necessary to obtain enough power of statistical value to 
evaluate these factors.  
6.4.2 Future directions 
Due to time constraints, feedback on the modules has been limited. This final step will verify the 
usefulness of these resources. The result of this project can be manipulated, updated, and tailored 
to benefit various audiences. Improvements in the illustrations could strengthen the quality of the 
guide. The outline and excerpts of the modules could also be used in materials pertaining to 
related cardiac conditions, such as long QT syndrome and CPVT. 
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